MET和HER2在胃癌中的表达及临床意义

MET and clinical meaning of HER2 expression in gastric cancer

目的分析胃癌人群中癌基因MET、人表皮生长因子受体2(HER-2)的蛋白表达及其与临床病理学特征的关系,为探索其对胃癌根治术患者复发及生存的预测价值。方法收集2007年2月20日至2013年2月20日来接受手术切除的胃或胃食管交界处腺癌患者标本共180例。采用En Vi Sion免疫组化法和FISH法对每个标本中的MET和HER2进行其相关的基因阳性表达水平进行检测,并对二者与患者的相关个人信息、病变部位、肿瘤的分化程度、有无转移等相关信息之间的线性相关关系进行研究。观察免疫组化评分与荧光原位杂交检测HER2的高表达与基因扩增之间的重叠率。统计患者两年内病死率。结果通过对180例胃癌患者进行免疫组化以及FISH方法检测HER2发现,HER2和MET的阳性表达率是40.0%和31.1%,基因扩增率是36.7%和34.4%,HER2和MET的高表达与基因扩增之间的重叠率是73.6%和78.6%,各个免疫组化间的重叠率比较差异有显著性(P<0.01)。MET表达与患者的个人信息、病变大小、病变部位以及是否出现淋巴道转移无关(P>0.05),而与分化程度、临床分期以及是否出现门脉侵犯有关(P<0.05);HER2表达与患者的个人信息、是否出现门脉侵犯、病变部位、是否出现淋巴道转移以及临床分期无关(P>0.05),而与分化程度与病变大小有关(P<0.05)。经过为期2年的随访工作发现,死亡率为33.3%(60/180),其中54例患者在检测过程中呈MET和HER2的双向高度表达。结论 MET和HER2的共同高度表达与胃癌患者病死率之间有相关性,HER2与肿瘤的分化程度和病变大小有关,MET与肿瘤分化程度和门脉侵犯有关,为今后临床上对胃癌患者癌基因的检测结果分析提供了重要的生物学资料。

Objective To detect the stomach cancer genes are MET in the crowd, the expression of HER2, analyze the relationship be- tween protein expression and the clinical pathology characteristic, study the correlation between protein expression and expression, and to explore its recurrence and survival in patients with gastric cancer radical predictive value. Methods Retrospectively collected on February 20, 2007 to February 2013, 20 days Ezhou center hospital surgical removal of the stomach or gastroesophageal junction specimen of 180 cases of adenocarcino- ma patients. By the method of EnViSion immunohistochemical method and the FISH, MET in each sample and its related HER,3 gene positive ex- pression level, and the two related to patient＇s personal information, lesion site, tumor differentiation degree, the linear relationships between those with and without transfer of information related to explore, to observe the immunohistochemical score with FISH detection with high expression of HER2 gene amplification rate of overlap between the Mortality statistics of two years. Results 180 patients to detect HER2 method and FISH found that HER2 and MET the positive expression rate was 40.0% and 31.1%, gene amplification rate were 36.7% and 34.4%, the high expression of HER2 and MET with gene amplification overlap rate is between 73.6% and 78.6%, the rate of overlap between the various significant difference （ P 〈 0.01 ）. MET expression and the patient＇s personal information, the lesion size, lesion area and whether has spread to the lymphatic channel （ P 〉 0.05 ） , and has nothing to do with the degTee of differentiation, clinical stage and whether any relevant portal vein invasion （ P 〈 0.05 ）. HER2 expression and the patient＇s personal information, whether any pathological changes of portal vein invasion, and whether any lymphatic channel not metastasis and clinical stage （ P 〉 0. 05 ）, and with the differentiation degree and the size of the lesions （ P 〈 0.05 ）. After a two - year follow - up work found that mortality was 33.3% （60/180）, among them 54 patients were MET in theprocess of testing and two - way high expression of HER2. Conclusion MET and common high expression of HER2 has correlation with mortality rates. The HER2 is associated with tumor differentiation degree and the lesion size. MET is associated with tumor differentiation degree and the portal vein invasion, for the future clinical cancer gene in patients with gastric cancer detection results analysis, which provides an important biological material.